NCT03502629View on ClinicalTrials.gov

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

PHASE2UnknownINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

July 2, 2018

Primary Completion Date

August 31, 2021

Study Completion Date

December 30, 2022

Conditions
Peripheral T Cell Lymphoma
Interventions
BIOLOGICAL

GB226

3mg/kg treat every 2 weeks

Trial Locations (1)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

Sponsors
All Listed Sponsors
lead

Genor Biopharma Co., Ltd.

INDUSTRY